Biotech News
Related news
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
GERNGeron2026-06-01 12:00 EST
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
LYELLyell Immunopharma2026-06-25 12:00 EST
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
LYELLyell Immunopharma2026-06-01 12:00 EST
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
REPLReplimune Group2026-05-31 12:00 EST
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
ZNTLZentalis2026-07-17 20:15 EST
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
CMPXCompass Therapeutics2026-07-17 14:42 EST
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
KURAKura Oncology2026-07-14 11:02 EST
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Exelixis
Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...
Recent company news
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
EXELExelixis2026-06-22 12:00 EST
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
EXELExelixis2026-05-30 14:00 EST
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
EXELExelixis2026-05-27 20:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Stock data
- Close
- 52.20 USD
- Market cap
- 12.2B USD
- Exchange
- NASDAQ
- Sector
- Small Molecule Drugs
- Location
- United States